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Abstract 
The purpose of this study was to compare a
novel bone marrow device with the standard
marrow needle in a prospective, randomized
study in a teaching hospital employing hema-
tologists-in-training.  The  new  device,  the
OnControl  Bone  Marrow  (OBM)  Biopsy
System,  utilizes  a  battery-powered  drill  to
insert the needle. Fifty-four bone marrows (27
standard and 27 OBM) were performed by 11
fellows under the observation and supervision
of 3 attending hematologists and 1 research
technologist.  The  primary  endpoint  of  the
study, the mean length of the marrow biopsy
specimens, a surrogate for marrow quality, was
determined by a pathologist in a blinded man-
ner. The mean length of the marrow biopsy
specimens was significantly longer (56%) for
the OBM group (15.3 mm) than for the stan-
dard  bone  marrow  (SBM)  group  (9.8  mm),
P<0.003. An objectively determined secondary
endpoint; mean procedure time, skin-to-skin;
also favored the OBM group (175 s) versus the
SBM group (292 s), P<0.007. Several subjec-
tive secondary endpoints also favored the OBM
group.  Only  minor  adverse  events  were
encountered  in  the  OBM  and  SBM  study
groups.  It  was  concluded  that  bone  marrow
procedures  (BMPs)  performed  by  hematolo-
gists-in-training were significantly faster and
superior in quality when performed with the
OBM compared to the SBM. These data sug-
gest that the OBM may be considered a new
standard of care for adult hematology patients.
OBM also appears to be a superior method for
training hematology fellows.
Introduction
The human bone marrow is often evaluated
in patients with various hematological disor-
ders,  including  anemia,  thrombocytopenia,
pancytopenia, leukemia and other hematologi-
cal malignancies.1 Multiple bone marrow pro-
cedures (BMP) are often required in patients
with  hematological  malignancies  to  guide
their  treatment.  The  instrument  customarily
employed, the Jamshidi needle, is designed to
yield both an aspirate and a marrow biopsy.
The BMP has changed very little in the last 40
years and involves a manual rotary insertion of
the Jamshidi needle into the marrow cavity of
the posterior aspect of the iliac bone. Although
local anesthesia for the skin, subcutaneous tis-
sues and periosteum is universally adminis-
tered,  the  BMP  is  regarded  by  patients  and
physicians alike as a painful and uncomfort-
able procedure.2-4In addition, suboptimal spec-
imens  including  dilute  aspirates  and  small
core biopsies are often obtained, limiting the
diagnostic potential of the procedure.
The conventional manual rotary technique
causes  excessive  periosteal  stimulation  con-
tributing to the pain. In addition, especially in
heavy patients, the biopsy length is often sub-
optimal due to limitation of depth that can be
reached  in  the  bone  by  manual  pressure.  A
new FDA-approved device for performing bone
marrows, the OnControl Bone Marrow Biopsy
System (OBM) was recently introduced by the
Vidacare  Corporation  (Shavano  Park,  TX,
USA). The OBM utilizes a battery-powered drill
to insert the marrow needle into the iliac bone
of  adult  hematology  patients.  Initial  clinical
studies  utilizing  the  OBM  system  indicated
that it was faster and easier to use for bone
marrow  aspirations  than  the  traditional
method.5 A few prospective studies comparing
the OBM with the standard bone marrow pro-
cedure (SBM) have been carried out to date.6-8
While the duration of the procedure has been
consistently shorter, and the core samples larg-
er  for  patients  undergoing  OBM  in  these
reports, no studies have been carried out in
teaching hospitals to determine whether or not
the OBM system will be more readily mastered
by  hematologists-in-training.  Instruction  of
hematology fellows in the BMP technique has
never  been  standardized,  varies  greatly
between different fellowship programs and sel-
dom receives high priority. As a result, fellows
completing  training  are  sometimes  not  well
versed in the performance of the BMP and tend
to avoid it in their post-fellowship careers. We
conducted a prospective, randomized study to
compare  the  OBM  procedure  with  the  SBM
procedure  in  adults.  The  length  of  marrow
biopsy  specimens  (a  surrogate  for  marrow
quality), aspirate quality and spicule content
and procedure time were assessed objectively
by the attending hematologist and pathologist.
The patient, fellow and attending also complet-
ed questionnaires grading the pain, procedure
difficulty, specimen quality and patient accept-
ability .
Materials and Methods
The  study  protocol  was  approved  by  the
Biomedical  Research  Alliance  of  New  York
Institutional  Review  Board.  Two  kits  were
used,  the  OBM  and  SBM.  The  OBM  system
consists of a battery-powered driver and a biop-
sy  needle  set.  The  driver  resembles  a  small
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hand-held  drill,  and  powers  a  single  lumen
needle into the medullary cavity of the adult
iliac bone. The needle set consists of two parts:
an outer cannula, 11 gauge by 4 or 6 inches
(102 or 152 mm) long; and a bevel-tip inner
stylet- used to penetrate the cortex. The SBM
device  used  in  the  study  was  typically  a
Jamshidi  bone  marrow  biopsy  needle  (11
gauge by 4 or 6 inches), which has a two-piece
T-handle design, a trocar-tapered stylet point
and a triple-crown cannula tip. All fellows sat-
isfactorily  completed  at  least  one  SBM  and
OBM procedure under the supervision of an
attending  hematologist,  before  they  were
deemed certified to start enrolling to the study.
Each fellow was initially randomized to per-
form either the SBM or the OBM. After the ini-
tial randomization the fellow then alternated
between  OBM  and  SBM  procedures  in  a
sequential  fashion.  Randomization  was  per-
formed for the fellows rather than the patients
to  minimize  differences  between  individual
fellows as to previous experience and variable
aptitude. 
After  giving  informed  consent,  adult
patients requiring bone marrow sampling pro-
cedures underwent either a SBM or an OBM.
Bone marrow aspiration and core biopsy were
obtained utilizing a one needle/one puncture
approach.  The  fellows  were  observed  and
supervised  throughout  the  procedure  by  an
attending hematologist or research technolo-
gist.  
The planned sample size was 102 patients,
51 by each technique. The primary endpoint of
the study was the mean length in millimeters
of the bone marrow specimens yielded by the
two techniques. The measured length of the
marrow biopsy specimen is a generally accept-
ed  surrogate  for  the  quality  of  the  marrow
biopsy. It was chosen as the primary endpoint
because that measurement was made in the
pathology department by a person who had no
knowledge of whether the specimen was OBM
or SBM and who was not involved in the study
in any way. 
Secondary  endpoints  included  the  skin  to
skin  procedure  time  in  seconds  as  well  as
other  endpoints  derived  from  the  question-
naires. The questionnaires were completed by
the patients, fellows and the attending hema-
tologist/research  technologist  immediately
after  the  procedure.  All  questions  were
answered on a 0 to 10 numerical scale. The
patient  questionnaire  included  questions
regarding the level of pain experienced, the
patient-perceived ease/difficulty of the proce-
dure and the degree of patient willingness to
have a repeat BMP if medically recommended.
The questionnaires completed by the fellows
included  questions  on  the  patient’s  level  of
pain, the ease/difficulty of the procedure and
the perceived quality of the bone marrow aspi-
rate and biopsy obtained. The questionnaires
completed by the attending hematologist or by
the  research  hematology  technologist  (who
observed  the  procedure)  included  questions
regarding the patient’s apparent level of pain,
the  ease/difficulty  of  the  procedure  and  the
perceived quality of the bone marrow aspirate
and biopsy obtained. Complications or adverse
events  were  recorded  during  the  procedure
and  at  patient  follow-up  evaluation.
Outpatients were called 1 or 2 days after the
BMP and their responses recorded. Inpatients
were visited 1 or 2 days after the BMP.
Statistical testing was conducted using SAS
Version  9  for  Windows  (SAS  Institute,  Cary,
NC).  Continuous  parameters  were  summa-
rized and compared between groups using a 2
sample  t-test.  Categorical  parameters  were
summarized  as  proportions  and  compared
using Fisher’s Exact test. Because most fellows
used  OBM  and  SBM  multiple  times,  linear
mixed effects models were fit to the data to
evaluate  differences  between  the  OnControl
and  Standard  methods  and  adjust  for  the
potential  correlation  in  repeated  measure-
ments from the same fellow. A priori signifi-
cance level was set at 0.05. An interim analysis
was planned after the first 51 patients were
accrued to determine if significant endpoints
had been reached to permit early termination
of the study.
Results
Two hospitals in the Bronx, NY participated
in  the  study,  Jacobi  Medical  Center  and
Montefiore Medical Center. A total of 54 BMPs
(27 SBM and 27 OBM) were performed by 11
hematology fellows under the observation of 3
attending hematologists and 1 research tech-
nologist. The mean age of the 54 patients was
58.9 (±15.1) years and 61.1% were male. The
mean height and weight were 168.1 (±11.0)
cm and 77.9 (±19.3) kg, respectively. For these
demographic parameters, there was statistical
homogeneity between the two groups (Table
1). Of the 54 patients in the study (Table 2), 11
(20.4%)  had  myeloma,  the  most  frequently-
occurring diagnosis. There was no significant
difference  in  the  frequency  of  diagnoses
between the two groups (P=0.563). 
The primary study endpoint, the mean mar-
row biopsy length was significantly longer in
Article
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Table 1. Patient demographics.
Demographic SBM OBM P
Number of male/female 16/11 16/11 0.609
Mean age (years±standard deviation) 60.7±16.3 57.2±14.0 0.399
Mean height (cm±standard deviation) 167.4±10.3 168.0±12.1 0.842
Mean weight (kg±standard deviation) 76.3±17.0 78.8±22.2 0.634
Body Mass Index 27.2±5.6 27.7±6.1 0.755
Race/Ethnicity: numbers of: 0.730
Black 14 10
Hispanic 9 12
Asian 23
White 22
Table 2. Patient diagnoses.
Diagnosis SBM OBM
Myeloma 74
Pancytopenia 35
Lymphoma, non-Hodgkin's 33
Anemia 25
Myeloproliferative disorder 32
Monoclonal gammopathy of undetermined significance 22
Myelodysplastic syndrome 13
Thrombocytopenia 21
Hodgkins lymphoma 11
Acute myeloid leukemia 10
IgM paraprotein 10
Metastatic carcinoma 10
Eosinophilia 0 1 [page 62] [Hematology Reports 2011; 3:e21]
the OBM group (15.3 mm) than in the SBM
group (9.8 mm), P<0.003 (Table 3). The mean
procedure time, a secondary endpoint, was sig-
nificantly shorter in the OBM group (175 s)
compared to the SBM group (292 s), P<0.007.
Other  secondary  endpoints  which  signifi-
cantly  favored  the  OBM  group  included  the
mean  pain  scores  recorded  by  the  fellows
(P<0.002) and by the attendings (P<0.008). In
regard to the mean pain scores reported by the
patients in the 2 study groups, a lower score
was tabulated in the OBM group (4.7) than in
the SBM group (5.9), but the difference was
not  significant  (P=0.11).  However,  patients
indicated  a  greater  willingness  to  have  a
repeat OBM (1.0) than a repeat SBM (2.9),
P<0.03. Both the fellows (2.6 vs. 5.0, P<0.002)
and attendings (3.0 vs 5.1, P<0.006) perceived
the OBM to be easier to perform than the SBM.
The attendings, but not the fellows, reported
superior biopsy specimens in the OBM vs. the
SBM group. The superiority of the OBM speci-
mens was verified by objective blinded meas-
urements  in  the  pathology  department.
However, the fellows and the attendings scored
the quality of the marrow aspirates as about
equal. There were a greater number (propor-
tion)  of  aspirates  scored  0  (dry  tap)  in  the
OBM group (7/25%) than in the SBM group
(4/15.4%), but the difference was not signifi-
cant (P=0.505).
There  were  no  serious  adverse  events  in
either the OBM or the SBM study groups. One
patient withdrew consent after an OBM was
begun. The needle had penetrated the cortex of
the  iliac  bone,  but  the  needle  could  not  be
detached from the driver in order to proceed
with  the  aspiration  and  biopsy.  That  needle
was withdrawn from the ilium. The BMP was
subsequently  performed  without  incident
using  a  standard  marrow  needle.  The  event
was  classified  as  a  device-related  complica-
tion.  Later,  the  manufacturer  modified  the
OBM needle attachment. After that, no further
incidents of that type were reported.
A minor adverse event occurred in a 56 year
old  man  hospitalized  for  gastrointestinal
bleeding,  cirrhosis  with  portal  hypertension,
thrombocytopenia and coagulation abnormali-
ties. He was being treated with red cell trans-
fusions  and  fresh  frozen  plasma.  Five  days
after an OBM, there was a spontaneous local
drainage of a soft tissue hematoma from the
posterior  iliac  marrow  biopsy  site.  This
responded to local and systemic therapy; the
patient  improved  and  was  subsequently  dis-
charged.  Another  minor  adverse  event
occurred in a 50 year-old female undergoing an
outpatient SBM, which was successfully com-
pleted.  Immediately  after  the  procedure,  the
patient  complained  of  numbness  and  weak-
ness  in  the  right  lower  extremity  and  was
unable to stand. The patient was transferred
via wheel chair to the emergency department,
where an aortic sonogram and an echocardio-
gram  were  performed  and  reported  normal.
Two  hours  after  the  SBM,  the  patient  was
examined by a neurologist who found that the
patient had completely recovered. The consult-
ant  felt  unable  to  distinguish  between  an
excess of local anesthetic adjacent to the right
sciatic nerve versus an anxiety reaction to a
difficult  procedure.  The  patient  was  dis-
charged from the emergency department and
followed  in  clinic.  She  had  no  further  right
lower  extremity  weakness  or  numbness  or
other neurological symptoms. There were no
other  adverse  events  encountered  in  either
study group.
Discussion
Since the introduction of the Jamshidi nee-
dle  for  BMPs  40  years  ago,  few  technical
advances  have  been  made  in  the  field.
Commercial introduction of the OBM, a battery
powered  drill  with  attached  needle  for  bone
marrow aspirations and biopsies, followed FDA
approval  of  the  device  in  2007.  Preliminary
studies indicated that the OBM was safe and
yielded adequate aspirates in a short period of
time.5 A  prospective  randomized  study  by
Berenson et al.,6 comparing OBM and SBM,
indicated that the OBM yielded bone marrow
biopsy specimens of significantly greater vol-
ume,  in  a  shorter  period  of  time,  with  less
residual pain in adult patients. A prospective,
randomized  study  of  OBM  versus  SBM  by
Swords  et  al.,7 using  experienced  operators,
indicated that significantly longer biopsy cores
were  obtained  with  the  OBM  method.  The
mean  biopsy  lengths  obtained  in  that  study
(13.1 mm OBM and 8.2 mm SBM) were very
similar to those obtained in the present study
(15.3 mm OBM and 9.8 mm SBM), as shown in
Table 3.
Thus, the primary endpoint in the present
study  confirmed  the  observation  that  the
length  of  the  marrow  biopsy  is  significantly
longer with the OBM method than with the
SBM method. The length of the marrow biopsy
is widely regarded as a surrogate for biopsy
quality.7 Since the only reason for subjecting
patients to this painful procedure is to obtain
diagnostic  information,  the  device  which
yields the most must be regarded as superior.
The fact that the primary endpoint of the study,
the length of the marrow core, was objectively
determined in the pathology laboratory (which
had no involvement in the study and no infor-
mation as to how individual specimens were
obtained),  underscores  the  objectivity  and
validity of the conclusion. An element of oper-
ator  bias  appeared  unlikely,  since  neophyte
hematologists  are  maximally  motivated  to
obtain  optimal  marrow  specimens.  A  pre-
planned interim analysis detected significant
differences, and, as a result, the study was ter-
minated early .
Other  OBM  studies  have  been  conducted
with experienced operators in clinical practice
settings.5-7 The present study is the first to be
conducted in teaching hospitals utilizing inex-
perienced  operators,  i.e.  hematologists-in-
training. The fact that the results were similar
whether the operators were experienced or not
confirms the ease with which the OBM tech-
nique is mastered. Indeed, the majority of the
participating  fellows  expressed  a  preference
for the OBM method which suggests that OBM
Article
Table 3. Study results: means±standard deviation.
Variable OBM SBM P
Objective
Device efficacy
Biopsy specimen length (mm) 15.3±7.3 9.8±6.7 0.003* 
(primary endpoint)
Procedure time (seconds) 174.6±105.1 292.1±210.0 0.007*
Subjective
Pain Scores 0-10
Perceived by patient 4.7±2.8 5.9±2.8 0.11
Reported by fellow 3.2±2.2 4.9±2.7 0.002*
Reported by attending 2.9±1.7 4.5±2.4 0.008*
Willingness by patient to repeat BMP 1.0±2.2 2.9±3.5 0.03*
Procedure ease/difficulty (0-10)
Reported by patient 1.1±1.7 2.2±3.3 0.11
Reported by fellow 2.6±2.6 5.0±2.8 0.002*
Reported by attending 3.0±2.6 5.1±3.4 0.006*
Perception of specimen adequacy (0-10)
Aspirate- fellow 5.0±3.3 5.4±2.7 0.59
Aspirate- attending 4.9±3.6 5.6±3.1 0.47
Core biopsy-fellow 6.4±1.9 5.1±3.1 0.07
Core biopsy-attending 6.7±2.0 4.8±3.4 0.01*
Number (proportion) of dry taps 7.0 (25.0%) 4.0 (15.4%) 0.505
*Indicates statistical significance[Hematology Reports 2011; 3:e21]
is a better training tool for teaching programs.
The key secondary endpoint of the study was
the  duration  of  the  procedure,  skin-to-skin.
The  mean  procedure  time  was  significantly
shorter with the OBM (174.6 s) than with the
SBM (292.1 s). In other words, even with inex-
perienced operators, OBM changed BMP from
a 5 minute procedure to a 3 minute procedure,
on  an  average.  Other  comparative  studies,
employing experienced operators, have report-
ed even faster OBM procedure times, and all
have demonstrated significantly shorter times
compared to a SBM control group.6-8 According
to Kuball et al, BMP time is particularly rele-
vant  to  patient  pain.2 Patients  are  generally
willing to undergo the BMP and a reasonable
level of pain, providing that the procedure time
is relatively short.
Pain scores, as reported by the patients, the
fellows  and  the  attending  hematologists/
research  technologist  were  also  secondary
endpoints  of  the  study.  The  patient-reported
pain scores showed a trend favoring OBM, but
the difference was not significant (P=0.11). A
similar result was reported by Berenson et al
who opined that the overall patient-reported
pain score is largely dominated by the sharp
pain of marrow aspiration. The latter would not
be expected to differ between various needles.
Both the fellows’ and the attendings’ percep-
tions  of  patient  pain  were  significantly  less
with OBM compared to SBM, a result subject to
observer bias. These data suggest there is a
need for clinicians to reconsider current pain
treatment options. These could include identi-
fying patients at risk for significant pain dur-
ing bone marrow procedures, discussing anal-
gesia and even sedation options with patients
including associated risks, and possibly re-dos-
ing during the procedure, particularly if multi-
ple punctures are required. 
Interestingly, the OBM patients expressed a
significantly  greater  willingness  to  have  a
repeat BMP than the SBM patients (P<0.03).
That result may be criticized as possibly sub-
ject to physician influence. However, another
possible  explanation  for  the  higher  level  of
patient willingness to have a repeat procedure
may be the difference in degree of procedure
difficulty  between  the  two  procedure  types.
Kuball noted that technical difficulties showed
a trend toward a more painful procedure.2 As
shown in Table 3, the Fellows did have more
difficulty with the SBM than with the OBM pro-
cedure.
Other  secondary  endpoints  included  the
scores assessing ease/difficulty of the proce-
dure by patients, fellows and attendings. On a
scale of 0-10 for procedure difficulty, patients
recorded a mean value of 1.1 for OBM and 2.2
for SBM. However, the difference was not sta-
tistically significant, owing to the wide stan-
dard deviation in both groups. On the other
hand,  the  fellows  and  attendings  rated  the
OBM procedure as significantly less difficult
than the SBM, a result subject to observer bias.
The questionnaire scores regarding quality of
marrow aspirates and biopsies from the fel-
lows and the attendings/research technologist
did not show notable differences between the
OBM and the SBM groups and were also sub-
ject to observer bias.
Refusal by patients to undergo BMPs, espe-
cially in diseases like myeloma, leukemia and
lymphoma, lead to delays in the diagnosis and
treatment which may have fatal consequences.
Any  device,  such  as  OBM,  which  promotes
greater  patient  acceptance  of  a  painful,  but
necessary,  procedure  may  be  anticipated  to
improve quality of care and to enhance favor-
able clinical outcomes.
Cost effectiveness is an ever present criteri-
on in the field of medical devices. The data pre-
sented in this and other OBM studies leave lit-
tle question as to the superior effectiveness of
OBM  when  compared  to  SBM.  In  a  study
involving 767 patients, Bishop et al reported
that only 42% of bone marrow biopsy speci-
mens were long enough for definitive diagno-
sis.9 The following points are relevant to the
cost portion of the equation. First, the battery
powered driver has a negligible cost since it
can be used for about 500 procedures. Second,
the  OBM  sterile  disposable  trays  retail  for
about $40 more than many SBM trays. But the
lower cost of SBM trays is offset by the inferi-
or quality of the marrow specimens, delays in
diagnosis  and  treatment,  the  necessity  of
repeating some BMPs, to say nothing of the
longer procedure time and the inferior patient
acceptance with the SBM. The long term costs
and consequences of training future hematol-
ogists with inferior devices are not readily cal-
culable.
Limitations
There were several limitations in this study.
As with other device studies, this study was
limited by the absence of blinding of patients ,
operators  or  observers.  The  noise  and  the
vibration of the OBM driver limited ability to
blind the study for the patients ; the operator or
observer could not be blinded for obvious rea-
sons. Although the primary endpoint (biopsy
length) and a secondary endpoint (procedure
time) were objectively determined, other sec-
ondary  endpoints  derived  from  the  various
questionnaires could not be free of observer
bias  or  physician  influence.  There  was  also
potential operator bias in the primary endpoint
since bone penetration by the operator might
be influenced by the fellow’s personal prefer-
ence for the SBM vs. OBM. Another limitation
was including data from multiple marrows for
different fellows, as opposed to one marrow of
each type per fellow, which would have taken
years to complete. There was also variability in
the number of marrows performed by each fel-
low, however this was partially offset by each
fellow alternating between the SBM and OBM.
Some  senior  fellows  also  had  greater  prior
experience with the SBM before they were cer-
tified for the study. However greater experi-
ence  with  the  SBM  would  have  shifted  the
results in favor of the SBM rather than OBM.
Finally, a detailed, blinded comparison of the
pathologic quality of OBM versus SBM speci-
mens was not carried out, owing to the omis-
sion of a specific consent phrase in the patient
consent  form.  Nonetheless,  blinded  observa-
tions of the OBM and the SBM biopsy speci-
mens by the hematopathologists did not reveal
any notable differences in the amount of mar-
ginal  necrosis  (as  might  be  caused  by  heat
denaturation),  hemorrhage,  aspiration  arti-
fact,  or  crush  artifact.  Both  OBM  and  SBM
biopsy specimens displayed variable aspiration
artifact, which was expected since the study
design mandated a one puncture/one needle
approach. 
Conclusions
The results of this first prospective, random-
ized trial in two teaching hospitals comparing
BMPs in OBM and SBM patients, as performed
by novice hematologists, indicate that signifi-
cantly longer and better quality marrow biopsy
cores may be obtained in a much shorter peri-
od of time, and with less patient pain when
using the OBM device. Adverse events were
inconsequential. The slightly greater expense
of OBM appears justifiable in balance. Wider
acceptance of OBM as a preferred BMP device
in  teaching  hospitals  may  lead  to  greater
acceptance of BMP as a necessary procedure
by patients, to improvements in the diagnosis
and  treatment  of  hematology/  oncology
patients and better training for fellows.
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